Clinical Scorecard: QUELL-DME Trial Gets Underway
At a Glance
| Category | Detail |
|---|---|
| Condition | Diabetic Macular Edema (DME) |
| Key Mechanisms | NLRP3 inflammasome inhibition, reduction of inflammatory processes |
| Target Population | Adults with diabetic macular edema |
| Care Setting | Phase 2 clinical trial |
Key Highlights
- First participant dosed in QUELL-DME trial
- Evaluating BGE-102 as monotherapy and in combination with anti-VEGF therapy
- Primary endpoint: change in best-corrected visual acuity at week 12
- Approximately 180 participants to be enrolled
- Topline results expected in the second half of 2027
Guideline-Based Recommendations
Diagnosis
- Assessment of diabetic macular edema through visual acuity tests
Management
- Consideration of BGE-102 as a treatment option in conjunction with standard anti-VEGF therapy
Monitoring & Follow-up
- Regular evaluation of best-corrected visual acuity and retinal parameters
Risks
- Potential for vascular leakage and vision loss associated with DME
Patient & Prescribing Data
Adults diagnosed with diabetic macular edema
BGE-102 is a novel oral NLRP3 inhibitor with a well-tolerated profile
Clinical Best Practices
- Monitor inflammatory biomarkers during treatment
- Evaluate the need for adjunct therapies in DME management
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
